safety of glp 1 receptor agonists Frontiers GLP-1 Receptor Agonists as Treatments

Ueda P, Soderling J, Wintzell V, Svanstrom H, Pazzagli L, Eliasson B, et al

Of these, the incretin hormone, glucagon-like peptide 1, is probably the most important

Inagaki N, Seino Y, Takeda J, Yano H, Yamada Y, Bell GI, et al

[DOI] [PMC free article] [PubMed] [Google Scholar] 62.Lahteenvuo M., Tiihonen J., Solismaa A., Tanskanen A., Mittendorfer-Rutz E., Taipale H

Candidates who typically benefit most from semaglutide therapy include individuals with obesity (defined medically as a body mass index of 30 or higher) or those who are overweight (with a BMI of 27 or higher) and experiencing weight-related health conditions such as elevated cholesterol, diabetes, or high blood pressure

doi: 10.1016/j.molmet.2024.101880 [DOI] [PMC free article] [PubMed] [Google Scholar] 244